Reportlinker.com announces that a new market research report is available in its catalogue:
Analgesics - A Worldwide Market Intelligence Report
http://www.reportlinker.com/p0164216/Analgesics---A-Worldwide-Market-Intelligence-Report.html
An aging baby boomer population and subsequent rise in geriatric population, and rising therapeutic benefits of pain treatment drugs (internal) are major factors driving growth in the global analgesics market. Expanding number of surgical procedures, and longer life of patients suffering from chronic illnesses such as cancer and AIDS further contribute to increased demand for analgesics. The market is characterized by the presence of a large number of patent-expired products.
Dynamics of the pain management drugs market witnessed significant changes in recent years. The failure of several drugs, considered initially as promisingly curative including recent unsuccessful COX-2 inhibitors, prompted manufacturers and researchers to undertake more research programs. There is a lucrative market for effective analgesics, which do not cause any adverse side effects.
These and other market data and trends are presented in "Analgesics: A Worldwide Market Intelligence Report" by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.
ANALGESICS BMR-1016
CONTENTS
1. METHODOLOGY 1
Study Reliability and Reporting Limitations 1
Disclaimers 2
Quantitative Techniques & Reporting Level 3
2. GLOBAL ANALGESICS MARKET OVERVIEW 4
Pain Therapeutic Market 4
Analgesics Market - Offering Immense Potential 4
Liquid Analgesics Register Rapid Growth 4
Neuropathic Pain - Unexplored 5
Ibuprofen Scoring High 5
External Analgesics - In a slump 5
Boom in Demand for Topical Analgesic Patches 5
3. PRODUCT FACTS 6
1. Internal Analgesics 6
Aspirin 6
Acetaminophen 6
Ibuprofen 6
Others (includes combination drugs) 6
2. External Analgesics 6
Combination Analgesics 6
4. MARKET TRENDS 7
Escalating R&D Costs: A Boon or Bane? 7
Cox II Crisis Tarnishes Industry Growth 7
Novel Therapies to Propel Opioid and Non-Opioid Therapies 8
Rx-to-OTC Switch 8
Why Consumers Prefer OTC Drugs? 8
Development of Analgesic Tripeptides 9
5. CORPORATE DEVELOPMENTS 9
Bayer to Acquire Sagmel's OTC Business 9
E5 Pharma Receives Approval from FDA 9
Pharmaceutical Associates Receives Approval from FDA 9
Concord Receives New Drug Approvals 9
Hisamitsu Receives Approval for SALONPAsO 9
Johnson & Johnson Submits NDA to FDA 10
Nycomed and Paladin Inks Joint-Promotion Agreement for Tridural 10
Akela Extends Agreement with Janssen 10
Daiichi and Lead Chemical Receives Approval for LoxoninO Tape 10
Tokio Marine Capital to Acquire Showa Yakuhin Kako 11
Corgenix Collaborates with Randox Laboratories 11
Corgenix Receives EPO Approval for Aspirin Resistance Method 11
IOL to Expand Production Capacity 11
American Oriental Bioengineering Partners with China Aoxing 11
Abraxis Takes Over Shimoda and its Subsidiary Company 11
ProEthic Pharmaceuticals Releases Ibudone for Acute Pain
Management 12
Dr. Reddy's Laboratories Introduces Supanac for Acute Pain
Management 12
PLx Initiates Clinical Trial For Aspirin-PC 12
Ranbaxy Receives Approval from FDA 12
Wockhardt Receives FDA Approval for DPN + APAP 12
Alpharma to Market Flector® Patch in the US 13
Auriga and Mikart Inks Agreement to Market Codein 13
Watson Receives FDA Approval for Oxycodone Hydrochloride and
Ibuprofen 13
Labopharm's Tramadol Receives Approval in Canada 13
Lion Acquires BUFFERIN® Trademark Rights 13
Grunenthal's Extends Licensing Agreement with Ortho-McNeil 14
China Aoxing Pockets LRT 14
Anesiva Inks Joint Venture Agreement Wanbang 14
Beijing Med-Pharm Inks Agreement with Lotus Healthcare 14
LAB International Inks Licensing Agreement with Janssen
Pharmaceutica 14
Three Sixty Pockets Rockford-Montgomery Labs 15
Antares Enters into License and Development Agreement for